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A ruptured aneurysm after stent graft puncture
during computed tomography-guided thrombin
injection
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Type II endoleaks occur in 5% to 10% of patients who are treated by endovascular aneurysm repair. A persistent type II
endoleak combined with documented aneurysm expansion is generally considered an indication for intervention.
Thrombin injection directly into the aneurysm sac is described as a safe and efficient treatment option. We present a
patient with a ruptured aneurysm caused by a puncture of the stent graft during computed tomography-guided thrombin
injection. This case highlights a possible harmful complication of thrombin injection and emphasizes the need for caution
while performing such a procedure. (J Vasc Surg 2010;52:1045-7.)The most common cause for persistent or renewed
pressurization of an aneurysm sac after endovascular aneu-
rysm repair (EVAR) is the early or late occurrence of an
endoleak. An endoleak is considered evidence of incom-
plete exclusion of the aneurysm sac from the circulation,
and it is therefore believed that endoleaks may eventually
lead to aneurysm rupture.
Endoleaks are divided into several subtypes, with type
II endoleaks being the most frequent.1 A type II endoleak
is caused by retrograde flow from a lumbar artery, the
inferior mesenteric artery, an accessory renal artery, or a
hypogastric artery into the aneurysm sac. Type II endoleaks
occur in about 5% to 10% of patients who are treated by
EVAR.2,3 An aggressive approach was adopted in the early
days of EVAR, and all type II endoleaks were treated in fear
of aneurysm rupture.4
Most large series assessing type II endoleaks have dem-
onstrated a relationship between persistent type II en-
doleaks and aneurysm sac expansion, reinterventions, and
even rupture. A correlation between aneurysm-related
death and type II endoleaks, however, has not been
shown.5,6 It was because of this relatively benign character
of type II endoleaks, combined with reintervention-related
complications, that a more conservative policy was adop-
ted.7,8 Nowadays, although some authors plead for an even
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doi:10.1016/j.jvs.2010.04.074more conservative policy, documented aneurysm expan-
sion is generally regarded an indication for reinterven-
tion.4,5,7,8
Several therapeutic options are available to treat type II
endoleaks. Owing to its minimally invasive nature and high
rate of technical success, transarterial coil embolization is
considered the therapy of choice.1,6 Transarterial emboli-
zation can be technically challenging, however. Thrombin
injections directly into the aneurysm sac are described as a
safe and efficient alternative with a high success rate and
fewer complications in several case series.9-12 Some there-
fore even favor direct translumbar embolization over
transarterial embolization for the treatment of type II en-
doleaks.9
We present a patient with an aneurysm rupture caused
by puncture of the endograft during thrombin injection to
highlight this potential complication and to emphasize the
need for caution while performing such a procedure.
CASE REPORT
Two years ago, an 89-year-old man was referred to our clinic
with an 8.4-cm asymptomatic abdominal aortic aneurysm (AAA).
The patient underwent an uneventful EVAR by placement of a
Talent bifurcated stent graft (Medtronic, Santa Rosa, Calif). Post-
operative computed tomographic angiography (CTA) showed
successful exclusion of the aneurysm sac, which was confirmed on
a duplex ultrasound (DU) imaging 6 months after EVAR. The
measured maximal aneurysm sac diameter at this time was 7.8 cm
(Fig 1, A). However, follow-up CTAs at 12 and 24 months
showed gradual expansion of the aneurysm sac up to 11 cm (Fig 1,
B). Although no endoleaks were identified on DU imaging and
CTA, a magnetic resonance angiogram (MRA) with a blood-pool
contrast agent showed a type II endoleak originating from a
lumbar artery.
The decision was made to treat this endoleak by a CT-guided
puncture of the aneurysm sac with injection of thrombin. With the
patient supine, CT guidance was used to pass a 21-gauge needle
from an anterior transabdominal approach into the aneurysm sac.
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Contrast was injected, which solely filled the aneurysm sac. Al-
though we had expected to measure a higher intrasac pressure, we
decided to aspirate the aneurysm sac and to proceed with the
intrasac thrombin injection.
A total of 300 mL of blood was aspirated, which reduced the
diameter of the AAA from 11 to 8 cm. Then, 2 mL of thrombin
(500 IU/mL, thrombin component of Tissucol Duo 500; Im-
muno, Vienna, Austria) was slowly injected. Because a postproce-
dural CT scan showed an AAA diameter of 10 cm, we decided to
obtain another CTA after 2 weeks and to repeat the procedure if the
AAA size had returned to the pre-embolization diameter of 11 cm.
The control CTA again showed a sac diameter of 11 cm along
with a type II endoleak. A second procedure, similar to the first,
was performed. The needle position during this second procedure
was confirmed by the aspiration of 20 mL blood (Fig 1, C).
Because no more fluid could be aspirated, the aneurysm was
thought to be partially thrombosed and only an additional 0.5 mL
of thrombin was injected.
Unfortunately, a DU study 3 months later revealed an aneu-
rysm diameter of 11 cm, together with a new endoleak of unknown
origin. A new CTA was planned, but before this scan, the patient
presented at the emergency department with progressive pain in
the abdominal region. A CTA showed a ruptured aneurysm (Fig 1,
D; Fig 2). During open surgical repair, a puncture was observed in
Fig 1. A, Computed tomography (CT) imaging on the second
postoperative day shows aneurysm reduction from 8.4 to 7.8 cm,
with no evident endoleak. B, At 2 years, the aneurysm had grown
to 11 cm, but there was no evident endoleak.C,CT imaging of the
second thrombin injection shows the needle clearly positioned
outside the stent graft. D, CT imaging 2 weeks after the second
thrombin injection shows aneurysm rupture and extravasation of
contrast (arrow) due to a type III endoleak.the main device of the stent graft, which was over-sutured. Themural thrombus was partially extracted, and the aneurysm sac was
reconstructed.
The patient’s postoperative course was uneventful and he was
discharged in good condition. A CTA 3 months later showed no
abnormalities.
DISCUSSION
Failure to exclude an aortic aneurysm completely from
the circulation remains the major weakness of EVAR. Indi-
cation and timing of secondary interventions are controver-
sial and equivocal due to a lack of evidence. Some EVAR
specialists advocate intervention if a type II endoleak per-
sists6 months, regardless of change in aneurysm sac size,
whereas others are more conservative.5,6,8 However, there
is general consensus that expansion of the aneurysm neces-
sitates intervention, although the risk of rupture due to a
type II endoleak is very low.3,5,8
A multitude of therapeutic options are available for the
treatment of type II endoleaks that range in their level of
invasiveness. Transarterial embolization was introduced in
1997, and its minimally invasive character and high techni-
cal success rate convinced many physicians of its superior-
ity.13 However, initial medium-term and long-term results
showed recurrent endoleaks in 60% to 91% of the patients.
Apart from the high recurrence rate, its applicability is
limited by the requisite to be able to catheterize the origin
of the side branches at the level of the wall of the aneurysm
sac.9,14
The high incidence of recurrent endoleaks in patients
Fig 2. A three-dimensional volumetric reconstruction shows a
type III endoleak originating in the main device of the stent graft.
The yellow arrow indicates the puncture hole, and the red circle
shows contrast extravasation.treated with transarterial embolization implies that embo-
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Baum et al9 suggested that endoleaks behave like arterial
malformations in which occlusion of the feeding vessel will
lead to recruitment of collaterals and, eventually, failure of
therapy.9 Hence, embolization of the entire aneurysm sac
prevents abnormal communication among these aortic
branches. A success rate of 92% reported for translumbar
embolization vs a failure rate of 80% in transarterial embo-
lization supports this hypothesis.9Moreover, a recent study
by Stavropoulos et al15 in which the endoleak cavity itself,
and not just the feeding artery, was embolized with a
transarterial technique gave similar results as the translum-
bar technique, with a 78.3% vs 72.6% clinical success.15 The
method chosen for the treatment of type II endoleaks
depends on the level of expertise and the technical feasibil-
ity of each technique.
Since the introduction of CT-guided thrombin injec-
tion, good results have been obtained and few complica-
tions reported.9,10,15 To the best of our knowledge, we are
the first to report rupture of an aneurysm due to an iatro-
genic type III endoleak from a puncture of the endograft
during a CT-guided thrombin injection. Although CT
provides excellent needle visualization, and direction and
depth can be visualized, it remains a procedure that has to
be thoughtfully planned and executed. The position of the
needle can be difficult to control in relationship to a pulsa-
tile moving stent graft because CT gives a static represen-
tation of a dynamic process.16
Needle entry under ultrasound visualization allows the
operator to accurately position the needle whilemonitoring
the thrombus formation and might prevent such incidents.
Disadvantages of this procedure are poor visualization of
the aorta due to air-filled bowel or obesity. Furthermore, an
ultrasound-guided puncture is operator-dependent and has
a relatively long learning curve.10,11 A good alternative is
therefore fluoroscopy combined with CTA. CT can verify
needle positioning, and fluoroscopic guidance allows real-
time embolization, thereby preventingmisplacement of the
needle or any embolic material.17
Nowadays, a more conservative approach is preferred in
the management of type II endoleaks. If intervention is nec-
essary, however, thrombin injection has proven to be an
effective method of treatment of a type II endoleak.9-12,15,17
This case clearly shows a potential negative adverse effect of
this procedure.
CONCLUSIONS
Caution should be used during the planning and exe-
cution of a CT-guided thrombin injection. We therefore
recommend meticulous needle verification with respect to
the change in aneurysm volume due to aspiration.
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